Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Want to see IONS full AI Analyst Report?
IONS Stock Chart & Stats
$75.71
-$0.75(-2.14%)
At close: 4:00 PM EST
$75.71
-$0.75(-2.14%)
Day’s Range― - ―
52-Week Range$31.66 - $86.74
Previous CloseN/A
Volume126.35K
Average Volume (3M)1.99M
Market Cap
$12.56B
Enterprise Value$14.38B
Total Cash (Recent Filing)$1.92B
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 05, 2026EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding165,262,560
10 Day Avg. Volume1,473,636
30 Day Avg. Volume1,990,425
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue13.59
Enterprise Value/Gross Profit13.82
Enterprise Value/Ebitda3.17
Forecast
1Y Price Target
$105.60Price Target Upside39.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-3.55
Revenue Forecast (FY)$885.74M
Bulls Say, Bears Say
Bulls Say
Clinical Outcomes And Payer ValuePhase 3 data showing a statistically significant reduction in acute pancreatitis establishes a clear clinical benefit that supports reimbursement and prescriber adoption.
Partner Licensing And Commercial De-riskingA licensing agreement that assigns ex-U.S. commercialization to a regional partner delivers upfront and milestone payments plus royalties while the partner funds regulatory filings and launches, lowering commercialization costs and providing near-term non-dilutive cash.
Regulatory Approval And Market ExpansionEuropean regulatory validation for an indication extension in severe hypertriglyceridemia enables commercialization outside the U.S., expands the treatable patient population and reduces execution risk in a major market.
Bears Say
Deal Economics UncertaintyUndisclosed timing and size of upfront, milestone and royalty payments create uncertainty about the exact ex-U.S. economics and the company's future revenue stream.
Leverage And Balance Sheet RiskElevated net debt relative to equity increases financial leverage and could constrain strategic flexibility and investor valuation.
Payer Access And Pricing PressureFailure of payer access assumptions or tougher payor negotiations could force increased discounts and lower net prices, limiting coverage and reducing peak sales potential.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $31.66 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $12.56B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 87 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.877 by $0.317.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.03.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 165,262,560 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.877. Following the earnings report the stock price went up 4.249%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$105.60 (39.48% Upside)
$105.60 (39.48% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 745.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
166.58%
12-Months-Change
Fundamentals
Return on Equity
-58.57%
Trailing 12-Months
Asset Growth
22.65%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and operational momentum—substantial year-over-year revenue growth (87%), meaningful milestone receipts (~$95M), multiple regulatory milestones and expanded product launches, plus an improved full-year revenue guide and tighter operating outlook. These positives are tempered by near-term headwinds from a price reset causing expected Q2 revenue pressure, elevated operating expenses and a large (but improving) non-GAAP operating loss, potential payer access timing delays, and an observed but described-as-managed hepatic fat signal in long-term data. On balance, the company’s growth drivers, expanded launch footprint, strengthened guidance and partner-led catalysts outweigh the challenges described.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$105.60
▲(39.48% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
0.74% Insiders
41.99% Mutual Funds
4.51% Other Institutional Investors
37.52% Public Companies and
Individual Investors